AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
AR and PI3K/AKT in Prostate Cancer: A Tale of Two Interconnected Pathways
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 24, Issue 3, Pages 2046
Publisher
MDPI AG
Online
2023-01-20
DOI
10.3390/ijms24032046
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer
- (2022) Xueliang Gao et al. MOLECULAR CANCER RESEARCH
- Trends in Incidence of Metastatic Prostate Cancer in the US
- (2022) Mihir M. Desai et al. JAMA Network Open
- Overall Survival Update for Patients with Metastatic Castration-resistant Prostate Cancer Treated with Capivasertib and Docetaxel in the Phase 2 ProCAID Clinical Trial
- (2022) Simon J. Crabb et al. EUROPEAN UROLOGY
- AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
- (2022) Seaho Kim et al. eLife
- Non-canonical androgen signaling pathways and implications in prostate cancer
- (2022) Versha Dahiya et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- Do androgen-directed therapies improve outcomes in prostate cancer patients undergoing radical prostatectomy? A systematic review and meta-analysis
- (2021) Ameeta L. Nayak et al. CUAJ-Canadian Urological Association Journal
- A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells
- (2021) Carlos M. Roggero et al. ONCOGENE
- Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer
- (2021) Alessandro Sciarra et al. ONCOLOGY
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Upregulation of potential regulatory signaling molecules correlate with androgen receptor splice variants AR-V7 and AR-V567es in prostate cancer metastasis
- (2021) Ilker Kiliccioglu et al. GENE
- Prostate cancer
- (2021) Richard J. Rebello et al. Nature Reviews Disease Primers
- Increased transcription and high translation efficiency lead to accumulation of androgen receptor splice variant after androgen deprivation therapy
- (2021) Tianfang Ma et al. CANCER LETTERS
- Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
- (2021) Kim N. Chi et al. JOURNAL OF CLINICAL ONCOLOGY
- Changing the History of Prostate Cancer with New Targeted Therapies
- (2021) Susana Hernando Polo et al. Biomedicines
- Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
- (2021) Christopher Sweeney et al. LANCET
- Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
- (2021) Mike Wenzel et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer
- (2021) Thanakorn Pungsrinont et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
- (2020) Cora N. Sternberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
- (2020) Neal D. Shore et al. NEW ENGLAND JOURNAL OF MEDICINE
- PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy
- (2020) Fabiana Conciatori et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors
- (2020) Yezi Zhu et al. ONCOGENE
- The Androgen Receptor in Prostate Cancer: Effect of Structure, Ligands and Spliced Variants on Therapy
- (2020) Elisabeth A. Messner et al. Biomedicines
- Targeting PI3K in cancer: mechanisms and advances in clinical trials
- (2019) Jing Yang et al. Molecular Cancer
- Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…
- (2019) Pedro C. Barata et al. CANCER
- ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
- (2019) Andrew J. Armstrong et al. JOURNAL OF CLINICAL ONCOLOGY
- PARP Inhibitors in Prostate Cancer—The Preclinical Rationale and Current Clinical Development
- (2019) Virtanen et al. Genes
- Abiraterone in “High-” and “Low-risk” Metastatic Hormone-sensitive Prostate Cancer
- (2019) Alex P. Hoyle et al. EUROPEAN UROLOGY
- Distinct functions of AKT isoforms in breast cancer: a comprehensive review
- (2019) Nico Hinz et al. Cell Communication and Signaling
- Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer
- (2019) Elisa M. Ledet et al. ONCOLOGIST
- Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial
- (2018) Lorenzo Tosco et al. BMC CANCER
- Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part I: Risk Stratification, Shared Decision Making, and Care Options
- (2018) Martin G. Sanda et al. JOURNAL OF UROLOGY
- MiR-135a Protects Vascular Endothelial Cells Against Ventilator-Induced Lung Injury by Inhibiting PHLPP2 to Activate PI3K/Akt Pathway
- (2018) Xiaodi Yan et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer
- (2018) Karim Fizazi et al. Clinical Genitourinary Cancer
- Alternative splicing in prostate cancer
- (2018) Alec Paschalis et al. Nature Reviews Clinical Oncology
- The role of ketoconazole in current prostate cancer care
- (2018) Vaibhav Patel et al. Nature Reviews Urology
- Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations
- (2018) E. David Crawford et al. PROSTATE CANCER AND PROSTATIC DISEASES
- 833PAZD8186, a potent and selective inhibitor of PI3Kβ/δ, as monotherapy and in combination with abiraterone acetate plus prednisone (AAP), in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC)
- (2018) J S de Bono et al. ANNALS OF ONCOLOGY
- Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY
- (2018) Scott T Tagawa et al. CLINICAL CANCER RESEARCH
- mTOR as a central hub of nutrient signalling and cell growth
- (2018) Joungmok Kim et al. NATURE CELL BIOLOGY
- Darolutamide (ODM-201) for the treatment of prostate cancer
- (2017) Neal D. Shore EXPERT OPINION ON PHARMACOTHERAPY
- Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide
- (2017) Emmanuel S. Antonarakis et al. JOURNAL OF CLINICAL ONCOLOGY
- AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate
- (2017) Tilman Todenhöfer et al. JOURNAL OF UROLOGY
- Androgen receptor splice variants and prostate cancer: From bench to bedside
- (2017) Kristine M. Wadosky et al. Oncotarget
- Androgen Signaling in Prostate Cancer
- (2017) Charles Dai et al. Cold Spring Harbor Perspectives in Medicine
- Clinical relevance of androgen receptor alterations in prostate cancer
- (2017) Emma Jernberg et al. Endocrine Connections
- Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance
- (2017) Daniel Crona et al. Cancers
- Cancer treatment and survivorship statistics, 2016
- (2016) Kimberly D. Miller et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer
- (2016) Helen Chow et al. CANCER
- Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
- (2016) Laura Graham et al. MEDICAL ONCOLOGY
- Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy
- (2016) Maxine Sun et al. JAMA Oncology
- Androgen Receptor Splice Variants Dimerize to Transactivate Target Genes
- (2015) D. Xu et al. CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models
- (2015) Paul Toren et al. EUROPEAN UROLOGY
- Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
- (2015) Ahmedin Jemal et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Predictive Value of PTEN and AR Coexpression of Sustained Responsiveness to Hormonal Therapy in Prostate Cancer—A Pilot Study
- (2015) Soha Salama El Sheikh et al. NEOPLASIA
- AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
- (2015) Gang Liu et al. NEOPLASIA
- Androgen receptor: structure, role in prostate cancer and drug discovery
- (2014) MH Eileen Tan et al. ACTA PHARMACOLOGICA SINICA
- Turning Off AKT: PHLPP as a Drug Target
- (2014) Alexandra C. Newton et al. Annual Review of Pharmacology and Toxicology
- PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance
- (2014) AndrewC Hsieh et al. ASIAN JOURNAL OF ANDROLOGY
- Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
- (2014) Z. Yu et al. CLINICAL CANCER RESEARCH
- Androgen receptor phosphorylation: biological context and functional consequences
- (2014) Yulia Koryakina et al. ENDOCRINE-RELATED CANCER
- Androgens and androgen receptor signaling in prostate tumorigenesis
- (2014) Ye Zhou et al. JOURNAL OF MOLECULAR ENDOCRINOLOGY
- PTEN loss is associated with upgrading of prostate cancer from biopsy to radical prostatectomy
- (2014) Tamara L Lotan et al. MODERN PATHOLOGY
- AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
- (2014) Emmanuel S. Antonarakis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
- (2014) Tomasz M. Beer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects
- (2014) R Ferraldeschi et al. ONCOGENE
- EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
- (2013) Axel Heidenreich et al. EUROPEAN UROLOGY
- Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
- (2013) Peter C. Albertsen et al. EUROPEAN UROLOGY
- Synergistic Targeting of PI3K/AKT Pathway and Androgen Receptor Axis Significantly Delays Castration-Resistant Prostate Cancer ProgressionIn Vivo
- (2013) Christian Thomas et al. MOLECULAR CANCER THERAPEUTICS
- Mechanisms of the androgen receptor splicing in prostate cancer cells
- (2013) L L Liu et al. ONCOGENE
- ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment
- (2012) N. J. Clegg et al. CANCER RESEARCH
- Androgen Receptor Splice Variants Mediate Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cell Lines
- (2012) Y. Li et al. CANCER RESEARCH
- The mutational landscape of lethal castration-resistant prostate cancer
- (2012) Catherine S. Grasso et al. NATURE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Steroid biosynthesis and prostate cancer
- (2012) Nima Sharifi et al. STEROIDS
- Negative Feedback and Adaptive Resistance to the Targeted Therapy of Cancer
- (2012) Sarat Chandarlapaty Cancer Discovery
- Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
- (2012) Yasser Rehman et al. Drug Design Development and Therapy
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1
- (2011) Changmeng Cai et al. CANCER CELL
- Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
- (2011) Brett S. Carver et al. CANCER CELL
- High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1
- (2011) Paige Yellen et al. CELL CYCLE
- A physiological role for androgen actions in the absence of androgen receptor DNA binding activity
- (2011) Tammy P.S. Pang et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- Time Trends and Local Variation in Primary Treatment of Localized Prostate Cancer
- (2010) Matthew R. Cooperberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
- (2009) Margaret A. Knowles et al. CANCER AND METASTASIS REVIEWS
- Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
- (2009) Christina Gewinner et al. CANCER CELL
- mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
- (2009) David A. Guertin et al. CANCER CELL
- Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer
- (2009) G. Attard et al. CANCER RESEARCH
- Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer
- (2009) Gerhardt Attard et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis
- (2009) C. Nardella et al. Science Signaling
- The regulation and function of Class III PI3Ks: novel roles for Vps34
- (2008) Jonathan M. Backer BIOCHEMICAL JOURNAL
- Timing of Androgen Deprivation Therapy and its Impact on Survival After Radical Prostatectomy: A Matched Cohort Study
- (2008) Sameer A. Siddiqui et al. JOURNAL OF UROLOGY
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis
- (2008) Shidong Jia et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started